Legato Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Legato Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$270K	Buy	+1,605	New	+$238K	0.02%	597

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legato Capital Management's NBIX Position: Q2 2026 in Review

Legato Capital Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,605 shares worth $270K. The stake represents 0.02% of the portfolio and ranks #597 among its holdings.

772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Legato Capital Management held 1,605 shares of Neurocrine Biosciences worth $270K as of Q2 2026.
Neurocrine Biosciences was a new Legato Capital Management position in Q2 2026.
Neurocrine Biosciences made up 0.02% of Legato Capital Management's portfolio in Q2 2026, its #597 holding.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.